Sacituzumab govitecan

Sacituzumab govitecan
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	Trop-2
Clinical data
Trade names	Trodelvy
Other names	IMMU-132, hRS7-SN-38, sacituzumab govitecan-hziy
AHFS/Drugs.com	Monograph
MedlinePlus	a620034
License data	US DailyMed: Sacituzumab govitecan;
Pregnancy; category	AU: D; Contraindicated;
Routes of; administration	Intravenous
ATC code	L01FX17 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1491917-83-9;
PubChem CID	91668186;
DrugBank	DB12893;
ChemSpider	none;
UNII	M9BYU8XDQ6;
KEGG	D10985;
ChEMBL	ChEMBL3545262;
CompTox Dashboard (EPA)	DTXSID401335985 ;
Chemical and physical data
Formula	C76H104N12O24S
Molar mass	1601.79 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O;
	InChI InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1; Key:ULRUOUDIQPERIJ-PQURJYPBSA-N;

Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.

The most common side effects include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain. Sacituzumab govitecan has a boxed warning about the risk of severe neutropenia (abnormally low levels of white blood cells) and severe diarrhea. Sacituzumab govitecan may cause harm to a developing fetus or newborn baby.

Sacituzumab govitecan was approved for medical use in the United States in April 2020, and in the European Union in November 2021. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consider it to be a first-in-class medication.